NOTICE: Summary decisions issued by the Appeals Court pursuant to M.A.C. Rule 23.0, as appearing in 97 Mass. App. Ct. 1017 (2020) (formerly known as rule 1:28, as amended by 73 Mass. App. Ct. 1001 [2009]), are primarily directed to the parties and, therefore, may not fully address the facts of the case or the panel's decisional rationale. Moreover, such decisions are not circulated to the entire court and, therefore, represent only the views of the panel that decided the case. A summary decision pursuant to rule 23.0 or rule 1:28 issued after February 25, 2008, may be cited for its persuasive value but, because of the limitations noted above, not as binding precedent. See Chace v. Curran, 71 Mass. App. Ct. 258, 260 n.4 (2008).
COMMONWEALTH OF MASSACHUSETTS
APPEALS COURT
22-P-1213
SOMERVILLE OFFICE ASSOCIATES LIMITED PARTNERSHIP
vs.
CRESSET DEVELOPMENT, LLC, & others. 1
MEMORANDUM AND ORDER PURSUANT TO RULE 23.0
Somerville Office Associates Limited Partnership (SOA)
filed a complaint in the Superior Court against Cresset
Development, LLC, and affiliate CDNV Land, LLC (Cresset), as
well as BRE-BMR Middlesex LLC (BioMed). The complaint alleged
that the defendants owed a substantial "earnout" payment and
raised five counts: (1) breach of contract (Cresset); (2)
breach of implied covenant of good faith and fair dealing
(Cresset); (3) successor liability (BioMed); (4) violation of
G. L. c. 93A (Cresset and BioMed); and (5) declaratory relief
(Cresset and BioMed). Cresset and BioMed moved to dismiss the
claims, and a judge allowed the motions. We affirm.
1 CDNV Land, LLC, and BRE-BMR Middlesex LLC. Background. In October 2016, SOA owned 5-7 Middlesex
Avenue in the Assembly Square neighborhood in the city of
Somerville. At that time, SOA and Cresset executed a letter of
intent for the sale of the property for $80 million. The
parties then executed a purchase and sale agreement on January
17, 2017 (Original PSA). Thereafter, the parties agreed to
split the transaction into two staggered sales, reduce the
purchase price to $65 million, and include an earnout provision
in connection with potential future development. Accordingly,
on March 23, 2017, the parties executed two new purchase and
sale agreements, one pertaining to an improved parcel containing
an existing office building, which would be sold first for $35
million (Improved PSA), and the second pertaining to an
unimproved parcel that would be sold later for $30 million
(Unimproved PSA).
The Unimproved PSA contained an earnout provision with a
formula for additional payments to SOA if building permits
issued within a five-year period to construct commercial space
that exceeded a certain square footage threshold. SOA
calculated the potential value of this earnout provision to be
nearly $20 million based on March 2016 master plans (Original
Master Plans) that it had previously commissioned and included
in the sale to Cresset. Although it retained discretion to
revise and edit the Original Master Plans, Cresset agreed to
2 provide monthly updates to SOA and to pursue municipal approval
of the Original Master Plans. Cresset purchased the improved
parcel in January 2018.
One month after the sale, Cresset presented SOA with new
master plans (Revised Master Plans). The Revised Master Plans
changed the development plan for both the improved and
unimproved parcels, reconfigured and redesigned the proposed
buildings, and substantially reduced the potential earnout to
just over $9 million. Despite the reduced earnout, SOA agreed
to amend the Unimproved PSA to incorporate the Revised Master
Plans. In June 2018, Cresset obtained municipal approval for
the Revised Master Plans. Cresset purchased the unimproved
parcel in January 2019.
Thereafter, Cresset ceased providing updates about the
development to SOA for several months. In November 2019,
Cresset unsuccessfully sought approval from SOA for a change in
the earnout provision relative to buildings that straddled the
improved and unimproved parcels. In the meantime, unbeknownst
to SOA, Cresset and BioMed developed, in March 2020, yet another
set of master plans (Final Master Plans) with an eye toward
demolishing the existing building and centering most development
on the improved parcel. In July 2020, municipal officials
approved the Final Master Plans. In January 2021, BioMed
purchased both the improved and unimproved parcels from Cresset
3 for nearly $200 million. On May 21, 2021, Cresset and BioMed
rejected SOA's demand for an earnout payment of more than $9
million and this civil action followed.
Cresset has conceded in its brief that while this appeal
was pending, building permits issued for construction on the
unimproved parcel. Because, in its view, the issuance of the
building permits triggered the earnout provision in the
Unimproved PSA, Cresset reports that it paid SOA $385,230.
Discussion. A motion to dismiss is properly allowed if a
complaint "[f]ail[s] to state a claim upon which relief can be
granted." Mass. R. Civ. P. 12 (b) (6), 365 Mass. 754 (1974).
We review the allowance of a motion to dismiss de novo, accept
as true the allegations in the complaint, and draw all
reasonable inferences in the plaintiff's favor. Curtis v. Herb
Chambers I-95, Inc., 458 Mass. 674, 676 (2011). When examining
the claims, we look beyond the conclusory allegations in the
complaint, examine the documents attached to the complaint, and
focus on whether the factual allegations plausibly suggest an
entitlement to relief. Iannacchino v. Ford Motor Co., 451 Mass.
623, 636 (2008); Schaer v. Brandeis Univ., 432 Mass. 474, 477
(2000).
1. Covenant of good faith and fair dealing. The covenant
of good faith and fair dealing provides that "neither party
shall do anything which will have the effect of destroying or
4 injuring the right of the other party to receive the fruits of
the contract." Druker v. Roland Wm. Jutras Assocs., 370 Mass.
383, 385 (1976), quoting Uproar Co. v. National Broadcasting
Co., 81 F.2d 373, 377 (1st Cir.), cert. denied, 298 U.S. 670
(1936). The complaint alleged that Cresset breached its duty of
good faith and fair dealing when it "abandoned" the project
outlined in the 2018 Revised Master Plans in favor of the Final
Master Plans crafted by Cresset and BioMed. Based on the
contractual provisions agreed on by SOA and Cresset as well as
their alleged conduct, the complaint fails to plausibly suggest
an entitlement to relief.
Contrary to SOA's contention, the complaint and attached
documents do not state that Cresset breached any duty owed to
SOA with respect to the Revised Master Plans. When SOA and
Cresset executed the Original PSA on January 17, 2017, they
agreed that the master plans could be modified during two
distinct time periods. Section 6.2 allowed SOA to change the
master plans under specified circumstances within forty-five
days of executing the Original PSA. At the expiration of that
forty-five day period, the "sole right" to change the master
plans shifted to Cresset under that same section. Section 6.1
Free access — add to your briefcase to read the full text and ask questions with AI
NOTICE: Summary decisions issued by the Appeals Court pursuant to M.A.C. Rule 23.0, as appearing in 97 Mass. App. Ct. 1017 (2020) (formerly known as rule 1:28, as amended by 73 Mass. App. Ct. 1001 [2009]), are primarily directed to the parties and, therefore, may not fully address the facts of the case or the panel's decisional rationale. Moreover, such decisions are not circulated to the entire court and, therefore, represent only the views of the panel that decided the case. A summary decision pursuant to rule 23.0 or rule 1:28 issued after February 25, 2008, may be cited for its persuasive value but, because of the limitations noted above, not as binding precedent. See Chace v. Curran, 71 Mass. App. Ct. 258, 260 n.4 (2008).
COMMONWEALTH OF MASSACHUSETTS
APPEALS COURT
22-P-1213
SOMERVILLE OFFICE ASSOCIATES LIMITED PARTNERSHIP
vs.
CRESSET DEVELOPMENT, LLC, & others. 1
MEMORANDUM AND ORDER PURSUANT TO RULE 23.0
Somerville Office Associates Limited Partnership (SOA)
filed a complaint in the Superior Court against Cresset
Development, LLC, and affiliate CDNV Land, LLC (Cresset), as
well as BRE-BMR Middlesex LLC (BioMed). The complaint alleged
that the defendants owed a substantial "earnout" payment and
raised five counts: (1) breach of contract (Cresset); (2)
breach of implied covenant of good faith and fair dealing
(Cresset); (3) successor liability (BioMed); (4) violation of
G. L. c. 93A (Cresset and BioMed); and (5) declaratory relief
(Cresset and BioMed). Cresset and BioMed moved to dismiss the
claims, and a judge allowed the motions. We affirm.
1 CDNV Land, LLC, and BRE-BMR Middlesex LLC. Background. In October 2016, SOA owned 5-7 Middlesex
Avenue in the Assembly Square neighborhood in the city of
Somerville. At that time, SOA and Cresset executed a letter of
intent for the sale of the property for $80 million. The
parties then executed a purchase and sale agreement on January
17, 2017 (Original PSA). Thereafter, the parties agreed to
split the transaction into two staggered sales, reduce the
purchase price to $65 million, and include an earnout provision
in connection with potential future development. Accordingly,
on March 23, 2017, the parties executed two new purchase and
sale agreements, one pertaining to an improved parcel containing
an existing office building, which would be sold first for $35
million (Improved PSA), and the second pertaining to an
unimproved parcel that would be sold later for $30 million
(Unimproved PSA).
The Unimproved PSA contained an earnout provision with a
formula for additional payments to SOA if building permits
issued within a five-year period to construct commercial space
that exceeded a certain square footage threshold. SOA
calculated the potential value of this earnout provision to be
nearly $20 million based on March 2016 master plans (Original
Master Plans) that it had previously commissioned and included
in the sale to Cresset. Although it retained discretion to
revise and edit the Original Master Plans, Cresset agreed to
2 provide monthly updates to SOA and to pursue municipal approval
of the Original Master Plans. Cresset purchased the improved
parcel in January 2018.
One month after the sale, Cresset presented SOA with new
master plans (Revised Master Plans). The Revised Master Plans
changed the development plan for both the improved and
unimproved parcels, reconfigured and redesigned the proposed
buildings, and substantially reduced the potential earnout to
just over $9 million. Despite the reduced earnout, SOA agreed
to amend the Unimproved PSA to incorporate the Revised Master
Plans. In June 2018, Cresset obtained municipal approval for
the Revised Master Plans. Cresset purchased the unimproved
parcel in January 2019.
Thereafter, Cresset ceased providing updates about the
development to SOA for several months. In November 2019,
Cresset unsuccessfully sought approval from SOA for a change in
the earnout provision relative to buildings that straddled the
improved and unimproved parcels. In the meantime, unbeknownst
to SOA, Cresset and BioMed developed, in March 2020, yet another
set of master plans (Final Master Plans) with an eye toward
demolishing the existing building and centering most development
on the improved parcel. In July 2020, municipal officials
approved the Final Master Plans. In January 2021, BioMed
purchased both the improved and unimproved parcels from Cresset
3 for nearly $200 million. On May 21, 2021, Cresset and BioMed
rejected SOA's demand for an earnout payment of more than $9
million and this civil action followed.
Cresset has conceded in its brief that while this appeal
was pending, building permits issued for construction on the
unimproved parcel. Because, in its view, the issuance of the
building permits triggered the earnout provision in the
Unimproved PSA, Cresset reports that it paid SOA $385,230.
Discussion. A motion to dismiss is properly allowed if a
complaint "[f]ail[s] to state a claim upon which relief can be
granted." Mass. R. Civ. P. 12 (b) (6), 365 Mass. 754 (1974).
We review the allowance of a motion to dismiss de novo, accept
as true the allegations in the complaint, and draw all
reasonable inferences in the plaintiff's favor. Curtis v. Herb
Chambers I-95, Inc., 458 Mass. 674, 676 (2011). When examining
the claims, we look beyond the conclusory allegations in the
complaint, examine the documents attached to the complaint, and
focus on whether the factual allegations plausibly suggest an
entitlement to relief. Iannacchino v. Ford Motor Co., 451 Mass.
623, 636 (2008); Schaer v. Brandeis Univ., 432 Mass. 474, 477
(2000).
1. Covenant of good faith and fair dealing. The covenant
of good faith and fair dealing provides that "neither party
shall do anything which will have the effect of destroying or
4 injuring the right of the other party to receive the fruits of
the contract." Druker v. Roland Wm. Jutras Assocs., 370 Mass.
383, 385 (1976), quoting Uproar Co. v. National Broadcasting
Co., 81 F.2d 373, 377 (1st Cir.), cert. denied, 298 U.S. 670
(1936). The complaint alleged that Cresset breached its duty of
good faith and fair dealing when it "abandoned" the project
outlined in the 2018 Revised Master Plans in favor of the Final
Master Plans crafted by Cresset and BioMed. Based on the
contractual provisions agreed on by SOA and Cresset as well as
their alleged conduct, the complaint fails to plausibly suggest
an entitlement to relief.
Contrary to SOA's contention, the complaint and attached
documents do not state that Cresset breached any duty owed to
SOA with respect to the Revised Master Plans. When SOA and
Cresset executed the Original PSA on January 17, 2017, they
agreed that the master plans could be modified during two
distinct time periods. Section 6.2 allowed SOA to change the
master plans under specified circumstances within forty-five
days of executing the Original PSA. At the expiration of that
forty-five day period, the "sole right" to change the master
plans shifted to Cresset under that same section. Section 6.1
provided additional language giving Cresset "the sole right to
determine what and when to develop" and the "sole discretion" to
"change or withdraw" the master plans. Cresset and SOA agreed
5 that these rights would survive the closing. This broad power
granted to Cresset continued to be included in the Unimproved
PSA executed on May 23, 2017, and survived the closing. The
conduct of the parties also suggested an understanding that the
master plans were never cast in concrete. As the complaint
alleges, prior to the closing, SOA and Cresset agreed in 2018 to
scrap the Original Master Plans in favor of the Revised Master
Plans. This significant change to the Original Master Plans
included both the improved and unimproved parcels and provided
for new buildings to straddle both parcels.
Thus, the complaint and supporting documents fail to
support SOA's contention that the master plans cabined Cresset's
business options and required Cresset (investing at least $65
million) to adhere to the Revised Master Plans come what may.
When Cresset created the Final Master Plans, it did so according
to a contractual right to exercise its "sole discretion" to
determine the scope of the development according to master plans
of its own choosing. "If the words of a contract are clear,
they are dispositive as to the meaning of the contract."
Columbia Plaza Assocs. v. Northeastern Univ., 493 Mass. 570,
581–582 (2024). Even if the Final Master Plans diminished the
value of SOA's earnout, the allegations of SOA's complaint do
not support an inference that Cresset failed to "remain faithful
to the intended and agreed expectations of the parties" as
6 documented. Uno Restaurants, Inc. v. Boston Kenmore Realty
Corp., 441 Mass. 376, 385 (2004).
SOA contends that Cresset's broad discretion with respect
to modifying the master plans was limited to addressing
municipal concerns in the permitting process and terminated on
Cresset's purchase of the unimproved parcel. There is nothing,
however, in the language of the Original PSA or the Unimproved
PSA, or any other document, that supports this contention.
Because SOA and Cresset did not include such language in their
various agreements, we are not at liberty to impose it on them
now. See Ayash v. Dana-Farber Cancer Inst., 443 Mass. 367, 385
(2005) ("[t]he scope of the covenant is only as broad as the
contract that governs the particular relationship"). "It is not
the role of the court to alter the parties' agreement." Rogaris
v. Albert, 431 Mass. 833, 835 (2000).
2. Application of the earnout provision. Failure to pay
money owed under the earnout provision could constitute a breach
of contract, but the complaint must indicate the earnout was due
and left unpaid. The complaint alleges that the earnout
provision applied to both parcels and was not paid according to
the Final Master Plans. Resolution of this claim turns on
whether the earnout applied to both parcels. Once again,
neither the complaint nor the attached documents support SOA's
claim.
7 The complaint does not show that Cresset breached the
earnout provision because the supporting documents show the
earnout provision applied only to the unimproved parcel.
"[W]here sophisticated parties choose to embody their agreement
in a carefully crafted document, they are entitled to and should
be held to the language they chose." Anderson St. Assocs. v.
Boston, 442 Mass. 812, 819 (2004). Here, SOA and Cresset split
the transaction into the Improved PSA and the Unimproved PSA on
May 23, 2017, and included the earnout provision only in the
Unimproved PSA. "In interpreting a written contract, such as a
purchase and sale agreement, the court gives full effect to all
the terms expressed by the parties." Rogaris, 431 Mass. at 835.
By including the earnout provision in the Unimproved PSA and
excluding the earnout provision in the Improved PSA, Cresset and
SOA expressed a clear intent that the earnout would be limited
to the unimproved parcel.
On appeal, SOA contends that the earnout provision, though
contained only in the Unimproved PSA, implicitly references both
the improved parcel and the unimproved parcel. While there is
no explicit reference to the improved parcel in the Unimproved
PSA, SOA argues that the various definitions and uses of the
terms "Property," "Land," "Project," and "on the Property"
throughout the agreements lead to the "inescapable conclusion"
8 that the earnout provision applies to both the unimproved and
improved parcels. We disagree.
SOA's interpretation, which would require reading "on the
Property" in the earnout provision to refer to something other
than real property, is not a reasonable one and cannot be
squared with the contractual language. Furthermore, beyond the
absence of any reference to the earnout provision in the
Improved PSA, we note that SOA, a sophisticated business
organization represented by counsel, missed a significant
opportunity to expressly include a reference to the improved
parcel in an amended earnout provision. This opportunity arose
after Cresset purchased the improved parcel. At that point,
Cresset and SOA agreed to the Revised Master Plans and executed
an amendment to the Unimproved PSA. In that amendment, the
terms of the earnout were modified, but no language linked the
earnout to the improved parcel. To the contrary, the amendment
referenced the "unimproved real property" and required a notice
of earnout to be recorded "just following the recording and
filing of the Deed for the Land" -- a clear reference to the
unimproved parcel that had not yet been conveyed. We also note
that the notice of earnout was recorded immediately following
the recording of the deed to the unimproved land. Especially
after the Revised Master Plans resulted in structures straddling
both parcels, SOA could have struck a more advantageous deal
9 that expressly extended the earnout to the improved parcel, but
it did not do so. As previously discussed, we cannot, in
hindsight, alter the parties' agreement. Rogaris, 431 Mass. at
835.
3. Other claims. Finally, we discern no basis for
successor liability, a 93A cause of action, or declaratory
relief. These claims are based on the same set of alleged facts
10 and fail under the same analysis. See Iannacchino, 451 Mass. at
635.
Judgment affirmed.
By the Court (Shin, Brennan & Hodgens, JJ. 2),
Assistant Clerk
Entered: May 29, 2024.
2 The panelists are listed in order of seniority.